Evidence for Cannabis in Cancer Pain
The National Academies of Sciences concluded in 2017 that there is "conclusive evidence" cannabis is effective for chronic pain — directly applicable to cancer pain management. A 2020 systematic review found 70-80% of cancer patients achieved meaningful pain reduction with cannabis. The multi-modal mechanism is key: THC reduces central pain sensitization while CBD reduces neuroinflammation and opioid tolerance. Cannabis also addresses the anxiety and depression that amplify cancer pain perception.
Cannabis for Chemo Side Effects
Chemotherapy-induced nausea and vomiting (CINV) has the longest clinical track record of any cannabis indication. Dronabinol (THC) and nabilone are FDA-approved specifically for CINV. Cannabis also addresses chemotherapy-induced peripheral neuropathy — the painful nerve damage causing tingling and burning in hands and feet. High-CBD tinctures reduce neuropathic pain while THC manages nausea and appetite loss (cachexia) simultaneously.
Integration with Oncology Care
Most oncologists now discuss cannabis with patients — the American Society of Clinical Oncology (ASCO) issued guidelines in 2018 supporting cannabis conversations. Cannabis rarely interacts with chemotherapy at therapeutic doses. The major interaction concern is with immunotherapy: high-dose THC may theoretically reduce immunotherapy efficacy — discuss with your oncologist. Cancer is a qualifying condition in virtually every US medical cannabis state.
Practical Use for Cancer Patients
For active cancer pain, patients often need higher doses than typical recreational users. Start with 5-10mg THC and escalate based on pain scores. Edibles provide the longest relief duration (6-8 hours) — important for overnight pain control. For nausea, inhaled or sublingual cannabis works faster than edibles. Palliative care specialists increasingly have cannabis expertise — request referral to integrative oncology programs at major cancer centers for the most comprehensive guidance.